ClinicalTrials.gg
Active, not recruitingNCT05749874ABCDUpdated Dec 31, 2025

Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus

A Phase 4 interventional study of Berberine plus lifestyle intervention and Placebo plus lifestyle intervention in PreDiabetes, Abdominal Obesity and Hypertension, sponsored by China National Center for Cardiovascular Diseases. Active, not recruiting at 1 site in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by China National Center for Cardiovascular Diseases · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,024
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 51 studies in Prediabetic State with a site in China — 24 open to participants now, 25 under way, 1 of them phase 3. Prediabetic State · China.

Enrollment
4th of 44
2,024 · median 160
Started
2023
with 4 others
Phase 4
8 of 51
3 open now
Primary completion
2026-12
later than 8 of 24 live
Registered
23rd of 51
by date

Among the 51 studies in Prediabetic State with a site in China, this one is the 4th largest by enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2023, is one of 8 in phase 4, reaches primary completion later than 8 of the 24 other live ones, and was the 23rd registered.

Prediabetic State

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

Browse Prediabetic State studies →

Open to participants now

24 of the 51 studies in Prediabetic State with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Prediabetic State with a site in China, or all of them as a file.
02

Study summary

This multicenter, double-blinded, randomized controlled trial aims to evaluate the effect of berberine on preventing cardiovascular disease and diabetes mellitus among individuals with high cardiometabolic risk in China.

Read the detailed description

The trial aims to evaluate the efficacy and safety of berberine treatment for individuals with high cardiometabolic risk. Potential eligible patients will be recruited from about 100 medical centers in China. After a 4-to-6-week run-in period with berberine, all the eligible participants will be randomized (1:1) to berberine 500mg twice a day plus lifestyle intervention (Arm A) or placebo plus lifestyle intervention (Arm B). The participants will be followed up at month 3 and month 6, and once every 3 months thereafter, and be followed up for 3 years.

03

Conditions studied

  • PreDiabetes
  • Abdominal Obesity
  • Hypertension
  • Dyslipidemias
  • Atherosclerotic Cardiovascular Disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged ≥40 years old
  • Participants with prediabetes, defined as (HbA1c) between 5.7% and 6.4%
  • Participants with >25kg/m2, or abdominal obesity (i.e., waist circumference ≥85 cm in female or waist circumference ≥90 cm in male)
  • Participants with established atherosclerosis cardiovascular diseases (ASCVD), or with at least two cardiovascular risk factors: (a) hypertension (b) aged ≥45(male) / 55 (female), (c) current smoker, (d) HDL-C\<1mmol/L or TG≥2.3mmol/L
  • Participants with established ASCVD required LDL-C≤70 mg/dL (1.8mmol/L) for participants with ASCVD or receiving optimized LDL-C-lowering therapy (at least moderate-intensity statin therapy, unless or intolerant)

Exclusion criteria

Exclusion Criteria:

  • Participants with FPG≥7.0 mmol/L, diagnosed with diabetes or taking oral glucose-lowering drugs
  • Participants diagnosed with acute coronary syndrome, stroke, , or undergoing cardiac surgery or cardiac intervention (i.e., implantation of cardiac closure devices, cardiac resynchronization therapy, or catheter ablation), percutaneous coronary intervention or valvuloplasty/other cardiac valve repair or implantation surgery within the 3 months before randomization
  • Participants who plan to perform coronary and/or non coronary revascularization surgery, or cardiac surgery within 6 months after randomization
  • Participants diagnosed with heart failure or \<40%, severe cardiac valvular disease, cardiomyopathy, congenital heart disease
  • Conditions known to interfere with the accuracy of measurement, including rheumatoid arthritis, hemolytic anemia, aplastic anemia, hemoglobinopathies, splenomegaly, splenectomy, vitamin B12 deficiency, alcoholism, long-term high-dose aspirin use, or chronic use of anesthetics or hydroxyurea
  • Recipients of major organ transplants (e.g., lung, liver, heart, bone marrow, kidneys, etc.)
  • Participants diagnosed with glucose-6-phosphate dehydrogenase (G6PD) deficiency
  • Participants taking berberine or drug containing berberine in the past 1 month
  • Participants with any adverse reaction to berberine
  • Participants with severe constipation, diarrhea, and/or severe chronic intestinal diseases (e.g., ulcerative colitis, Crohn's disease, irritable bowel syndrome, etc.)
  • Participants who plan to have weight loss surgery, plan to take or currently taking drugs for weight loss
  • Participants with active liver diseases, or (ALT) / aspartate aminotransferase (AST) > 3 times
  • Estimated (eGFR) \< 45 ml/(min×1.73m2)
  • Women who are pregnant or breastfeeding, or those who plan to be pregnant during the trial
  • Participants with malignant tumors, or other serious diseases with of less than 3 years
  • Participants with mental disorders, cognitive disorders, or other serious diseases that could affect study participation
  • Participants who participated or have been participating other trials during the last 3 months
  • Any other conditions that may hinder the compliance to the study intervention or follow-up visit
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,024 participants (actual)

Study arms

  • Experimental
    berberine group

    Berberine hydrochloride plus lifestyle intervention

    Drug: Berberine plus lifestyle intervention

  • Placebo comparator
    placebo group

    Placebo plus lifestyle intervention

    Behavioral: Placebo plus lifestyle intervention

Interventions

  • DrugBerberine plus lifestyle intervention

    berberine hydrochloride 500mg twice a day plus lifestyle intervention. Lifestyle intervention is based on Chinese guideline for primary prevention of cardiovascular diseases, and Chinese guideline for management of type 2 diabetes mellitus, coronary heart disease, myocardial infarction and stroke. Intervention includes health education on smoking, alcohol consumption, diet, physical activity and weight loss, etc.

  • BehavioralPlacebo plus lifestyle intervention

    Placebo with identical shape, colour, odour and taste twice a day plus lifestyle intervention. Lifestyle intervention is based on Chinese guideline for primary prevention of cardiovascular diseases, and Chinese guideline for management of type 2 diabetes mellitus, coronary heart disease, myocardial infarction and stroke. Intervention includes health education on smoking, alcohol consumption, diet, physical activity and weight loss, etc.

06

What researchers measure

Primary outcomes

  1. The distribution of glycemic status at 1 year after randomization

    Categorized as normal glucose metabolism, prediabetes, and diabetes

    Time frame: Intervention Period: 1 year

Secondary outcomes

  1. Changes of glycemic-related parameters

    Including hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), homeostasis model assessment of insulin resistance (HOMA-IR), and homeostasis model assessment of β-cell function (HOMA-β)

    Time frame: Intervention Period: 1 year

  2. Changes of lipid-related parameters

    Including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and lipoprotein(a)

    Time frame: Intervention Period: 1 year

  3. Change of inflammation-related marker

    Including high-sensitivity C-reactive protein (hs-CRP)

    Time frame: Intervention Period: 1 year

  4. Change of physical examination measures

    Including body mass index (BMI) and waist circumference

    Time frame: Intervention Period: 1 year

  5. Changes of other parameters

    Including urinary albumin-to-creatinine ratio (UACR), serum uric acid, and metabolic syndrome score

    Time frame: Intervention Period: 1 year

  6. Change of depressive symptoms

    Measured by Patient Health Questionnaire-9 (PHQ-9)

    Time frame: Intervention Period: 1 year

  7. Time to first occurrence of composite endpoint of major cardiovascular event and diabetes

    cardiovascular death, non-hemorrhagic stroke, myocardial infarction, arterial revascularization, and diabetes

    Time frame: Intervention Period: 1 year

  8. Time to new-onset diabetes

    Diabetes is determined by oral glucose tolerance test, clinical diagnosis or use of glucose-lowering medications.

    Time frame: Intervention Period: 1 year

  9. Normalization of glucose parameters

    Meeting all three criteria: 1) Fasting plasma glucose (FPG)\<6.1 mmol/L; 2) 2-hour postprandial blood glucose (2hPG)\<7.8 mmol/L; 3) HbA1c\<5.7%.

    Time frame: Intervention Period: 1 year

  10. Time to newly diagnosed cancer

    all events of cancer or classified by primary sites

    Time frame: Intervention Period: 1 year

  11. Exploratory biomarker analyses

    Including serum trimethylamine, trimethylamine N-oxide, dopamine, berberine metabolites, and lipidomics analyses; urinary berberine metabolite analyses; and gut microbiota sequencing analyses.

    Time frame: Intervention Period: 1 year

  12. Time to first occurrence of composite endpoint of major cardiovascular event and diabetes

    cardiovascular death, non-hemorrhagic stroke, myocardial infarction, arterial revascularization, and diabetes

    Time frame: Entire follow-up period: 4 years

  13. Time to new-onset diabetes

    Diabetes is determined by oral glucose tolerance test, clinical diagnosis or use of glucose-lowering medications.

    Time frame: Entire follow-up period: 4 years

  14. Time to first occurrence of composite endpoint of major cardiovascular event 1

    cardiovascular death, non-hemorrhagic stroke, myocardial infarction, arterial revascularization

    Time frame: Entire follow-up period: 4 years

  15. Time to first occurrence of composite endpoint of major cardiovascular event 2

    cardiovascular death, non-hemorrhagic stroke, myocardial infarction

    Time frame: Entire follow-up period: 4 years

  16. Time to newly diagnosed cancer

    all events of cancer or classified by primary sites

    Time frame: Entire follow-up period: 4 years

Other outcomes

  1. Subgroup analysis 1 for primary outcome measure

    Age (\<55,55-65,≥65)

    Time frame: Intervention Period: 1 year

  2. Subgroup analysis 2 for primary outcome measure

    Sex (male, female)

    Time frame: Intervention Period: 1 year

  3. Subgroup analysis 3 for primary outcome measure

    Body mass index (\<28kg/m2, ≥28kg/m2)

    Time frame: Intervention Period: 1 year

  4. Subgroup analysis 4 for primary outcome measure

    Statin use (yes, no)

    Time frame: Intervention Period: 1 year

  5. Subgroup analysis 5 for primary outcome measure

    HbA1c median

    Time frame: Intervention Period: 1 year

  6. Subgroup analysis 6 for primary outcome measure

    Hs-CRP tertiles

    Time frame: Intervention Period: 1 year

  7. Subgroup analysis 7 for primary outcome measure

    LDL-C tertiles

    Time frame: Intervention Period: 1 year

  8. Subgroup analysis 8 for primary outcome measure

    Triglyceride tertiles

    Time frame: Intervention Period: 1 year

  9. Subgroup analysis 9 for primary outcome measure

    HDL-C tertiles

    Time frame: Intervention Period: 1 year

  10. Safety assessment during the intervention period

    Including serious adverse events, non-serious adverse events of special interest, and treatment discontinuation for any reason

    Time frame: Intervention Period: 1 year

07

Study locations

1 site
08

References and documents

Publications

  • Kong WJ, Vernieri C, Foiani M, Jiang JD. Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders. Pharmacol Ther. 2020 May;209:107496. doi: 10.1016/j.pharmthera.2020.107496. Epub 2020 Jan 27. PubMed 32001311 ↗
  • Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004 Dec;10(12):1344-51. doi: 10.1038/nm1135. Epub 2004 Nov 7. PubMed 15531889 ↗

Individual participant data

Plan to share: Undecided — All the IPD that underlie results in the publication with study protocol and SAP will be shared to the public on the study website upon request with a protocol after approval from the ABCD steering committee. The access criteria and URL of the study website is not established yet.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2026, 38 months after the start.

Of 30 phase 4 interventional studies under Prediabetic State, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 47. This study's planned 38 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2023
First posted
Mar 1, 2023
StartActual
Oct 31, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05749874
Responsible party
Sponsor
First posted
Mar 1, 2023
Start date
Oct 31, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 31, 2025

Study contacts

Jing Li, PhD
principal investigator · National Center for Cardiovascular Diseases
Haibo Zhang, MD
principal investigator · National Center for Cardiovascular Diseases

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion